卡茚西林 | 26605-69-6

• 物质功能分类: 原料药 - 抗生素类药物 - 青霉素类药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 中文名称: 卡茚西林
• 英文名称: Carbenicillin indanyl sodium (300 MG)
• CAS: 26605-69-6
• 化学式: C26H26N2NaO6S
• 分子量: 517.6
• InChiKey: MIDVDPGGKUZZAJ-XZVIDJSISA-N

物化性质

• 熔点：
  207-213°
• 溶解度：
  DMSO（微溶）、水（微溶、加热、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  2.12
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2941106000

文献信息

• Suppository and composition comprising at least one polyethylene glycol
  申请人：Anestic ApS

  公开号：US20020048601A1

  公开（公告）日：2002-04-25

  There is provided a suppository comprising at least one biocompatible polymer, wherein the biocompatible polymer is essentially non-biodegradable, and wherein the suppository essentially does not swell when contacted with an aqueous fluid. The suppository may further comprise a plurality of open cells at least partly separated from one another by an interpenetrating matrix comprising at least one biocompatible polymer in branched or crosslinked form. The plurality of interlinked, open cells are capable of containing an aqueous fluid, and the permeability of the suppository ensures that entry of body fluids into the open cells under practical circumstances occurs essentially without dehydration of mucousal membrane tissue contacting the suppository. The suppository furthermore preferably comprises a controlled release formulation.

  提供了一种含有至少一种生物相容性聚合物的栓剂，其中该生物相容性聚合物基本上不可生物降解，且当与水性液体接触时，该栓剂基本上不膨胀。该栓剂还可以进一步包括多个开放单元，这些单元至少部分地由相互穿插的基质分隔开，该基质包含至少一种分支或交联形式的生物相容性聚合物。这些互相连接的开放单元能够包含水性液体，而栓剂的渗透性确保体液进入开放单元时，在实际情况下基本上不会导致接触栓剂的粘膜组织脱水。此外，该栓剂最好包含控制释放配方。
• SUSTAINED RELEASE SUPPOSITORY
  申请人：SS PHARMACEUTICAL CO., LTD.

  公开号：EP0531524A1

  公开（公告）日：1993-03-17

  A sustained release suppository containing an acidic drug or its salt absorbable by rectal application and an acidic material or a pH buffer. It does not cause abrupt rise of the blood concentration immediately after being applied and has a long duration of action, so that it is not only safer but also excellent in curing effects.

  一种缓释栓剂，内含可通过直肠应用吸收的酸性药物或其盐，以及酸性材料或 pH 缓冲剂。它不会在使用后立即导致血液浓度突然升高，而且作用时间长，因此不仅更安全，而且疗效极佳。
• CRYSTALLINE CONDITION DISLOCATING METHOD
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0665009A1

  公开（公告）日：1995-08-02

  An object of this invention is to provide a method of dislocating the crystalline condition of crystalline medicine simply, speedily and homogeneously, and, moreover, in large quantities at once. This invention is directed to a method using an extruder when crystalline medicine in a certain crystalline condition (△ is dislocated to another crystalline condition (○), i.e., when the dislocation of crystalline condition (△->○) is carried out.

  本发明的目的是提供一种简单、快速和均匀地将结晶药物的结晶状态变位的方法，而且是一次性大量变位。本发明针对的是一种使用挤压机将某种结晶状态（△）的结晶药物变位到另一种结晶状态（○）的方法，即结晶状态（△->○）变位的方法。
• LIPOSOMES
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP1190706A1

  公开（公告）日：2002-03-27

  Drug carriers that includes a drug, being very high in targeting capability at a diseased site such as an inflammatory site or a tumor site where pH has been decreased in acidic regions. A liposome, comprising as membrane constituents [1] a basic compound, [2] an acidic compound which is a phosphoric acid monoester derivative, or a compound having a carboxyl group or its salt, and [3] other liposome constituent.

  药物载体，包括药物，在酸性区域 pH 值降低的炎症部位或肿瘤部位等病变部位具有很强的靶向能力。一种脂质体，其膜成分包括[1]碱性化合物，[2]磷酸单酯衍生物或具有羧基的化合物或其盐类的酸性化合物，以及[3]其他脂质体成分。
• Liquid polymer composition for prevention and treatment of the oral cavity diseases
  申请人：Italmed S.N.C. Di Galli G. & Pacini G.

  公开号：EP1262172A1

  公开（公告）日：2002-12-04

  A new composition for treating periodontal disease by means of a therapeutic agent delivery device placed within the periodontal pocket so that release of the therapeutic agents occurs in the immediate vicinity of the disease process, without that a release adjusting agent or adhesive agent is present so that biocompatibility or allergic problems cannot arise. A slow release of a therapeutic agent is obtained as well as a mechanical protection on the wounds and a barrier to bacteria. The a composition comprises a therapeutic agent in a biocompatible polymeric material. The therapeutic agent is soluble both in water and in alcohol and the biocompatible polymeric material is a liquid methacrylate copolymer chosen among EUDRAGIT RL or EUDRAGIT RS or a mixture thereof. The polymers are provided as a liquid in an alcoholic suspension, preferably about 95%. When the polymer is spread on a surface, the alcohol evaporates and the polymer forms a polymeric film on that surface. When water present in the mouth tissues permeates through the material, the therapeutic agent is released. By proper selection of the two polymeric material EUDRAGIT RS and RL, a precise release rate is obtained. In fact, by varying the ratio RS/RL the hydrophilic property varies accordingly. In particular, if RL is increased, the release rate of the therapeutic agent is increased.

  一种用于治疗牙周病的新型组合物，通过将治疗剂输送装置放置在牙周袋内，使治疗剂在疾病过程附近释放，同时不需要释放调节剂或粘合剂，因此不会出现生物相容性或过敏问题。这样既能实现治疗剂的缓慢释放，又能为伤口提供机械保护并阻隔细菌。该组合物由生物相容性聚合物材料中的治疗剂组成。治疗剂可溶于水和酒精，生物相容性聚合物材料是一种液态甲基丙烯酸酯共聚物，可从 EUDRAGIT RL 或 EUDRAGIT RS 或它们的混合物中选择。聚合物以酒精悬浮液的形式提供，浓度最好在 95% 左右。当聚合物涂抹在表面上时，酒精蒸发，聚合物在表面上形成一层聚合物薄膜。当口腔组织中的水分渗透过该材料时，治疗剂就会释放出来。通过适当选择 EUDRAGIT RS 和 RL 这两种聚合物材料，可以获得精确的释放率。事实上，通过改变 RS/RL 的比例，亲水性能也会相应变化。特别是，如果 RL 增加，治疗剂的释放率也会增加。